Orthofix International NV (OFIX) : North Tide Capital has sold out all of its stake in Orthofix International NV during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 500,000 shares of Orthofix International NV which is valued at $21,765,000.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc reduced its stake in OFIX by selling 28,351 shares or 29.48% in the most recent quarter. The Hedge Fund company now holds 67,809 shares of OFIX which is valued at $2,951,726.Ajo Lp boosted its stake in OFIX in the latest quarter, The investment management firm added 5,725 additional shares and now holds a total of 66,849 shares of Orthofix International NV which is valued at $2,839,077. Orthofix International NV makes up approx 0.01% of Ajo Lp’s portfolio.Gamco Investors Et Al reduced its stake in OFIX by selling 2,800 shares or 2.82% in the most recent quarter. The Hedge Fund company now holds 96,325 shares of OFIX which is valued at $4,086,107. Orthofix International NV makes up approx 0.03% of Gamco Investors Et Al’s portfolio.Gsa Capital Partners Llp boosted its stake in OFIX in the latest quarter, The investment management firm added 32,920 additional shares and now holds a total of 82,612 shares of Orthofix International NV which is valued at $3,504,401. Orthofix International NV makes up approx 0.18% of Gsa Capital Partners Llp’s portfolio.
Orthofix International NV opened for trading at $44.94 and hit $45.77 on the upside on Wednesday, eventually ending the session at $45.76, with a gain of 1.82% or 0.82 points. The heightened volatility saw the trading volume jump to 83,300 shares. Company has a market cap of $829 M.
On the company’s financial health, Orthofix International NV reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 1, 2016. Analyst had a consensus of $0.33. The company had revenue of $104.08 million for the quarter, compared to analysts expectations of $102.40 million. The company’s revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 EPS.
Orthofix International N.V. (Orthofix) is a diversified global medical device company focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians across the world. The company operates in four segments: BioStim Biologics Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim Spinal-Stim and Physio-Stim. Its Biologic solutions products include AlloQuent Structural Allografts Trinity ELITE and Trinity Evolution among others. Its Extremity Fixation solutions include Fixator and Galaxy Fixation System among others. Its Spine Fixation solutions products include NewBridge Laminoplasty Fixation System and PILLAR PL & TL PEEK VBR System among others. It uses independent distributors as well as directly distributes its products in the United States Italy the United Kingdom Germany Switzerland Austria France Brazil Australia and Puerto Rico.